Health Care & Life Sciences » Pharmaceuticals | La Jolla Pharmaceutical Co.

La Jolla Pharmaceutical Co. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
8,666.00
48,592.00
126,704.00
65,926.00
90,915.00
172,604
Other Current Assets
43.00
1,665.00
841.00
1,505.00
3,147.00
5,111
Total Current Assets
8,709.00
50,257.00
127,545.00
67,431.00
94,062.00
181,116
Net Property, Plant & Equipment
38.00
279.00
1,732.00
3,145.00
24,568.00
22,267
Total Investments and Advances
-
-
-
-
909.00
909
Other Assets
-
-
70.00
219.00
-
-
Total Assets
8,747.00
50,536.00
129,347.00
70,795.00
119,539.00
204,292
Accounts Payable
834.00
730.00
2,506.00
6,652.00
-
Other Current Liabilities
260.00
1,350.00
2,314.00
3,106.00
18,552.00
Total Current Liabilities
1,094.00
2,080.00
4,820.00
9,758.00
18,552.00
Other Liabilities
-
-
-
-
12,785.00
Total Liabilities
1,094.00
2,080.00
4,820.00
9,758.00
31,337.00
Common Equity (Total)
2,613.00
41,741.00
117,884.00
54,394.00
81,559.00
Total Shareholders' Equity
7,653.00
48,456.00
124,527.00
61,037.00
88,202.00
Total Equity
7,653.00
48,456.00
124,527.00
61,037.00
88,202.00
Liabilities & Shareholders' Equity
8,747.00
50,536.00
129,347.00
70,795.00
119,539.00
Preferred Stock (Carrying Value)
10,266.00
6,715.00
6,643.00
6,643.00
6,643.00

About La Jolla Pharmaceutical

View Profile
Address
4550 Towne Centre Court
San Diego California 92121
United States
Employees -
Website http://www.lajollapharmaceutical.com
Updated 07/08/2019
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. LJPC-501 is the proprietary formulation for angiotensin II.